Wes Sundquist | The role of biochemistry in transforming HIV treatment and prevention

Value of the Information & Strength of the Argument

The talk provides exceptional value by connecting fundamental biochemistry to a life-saving drug. Sundquist’s argumentation is solid, based on decades of peer-reviewed research and clinical trial data. He clearly explains the scientific rationale for targeting the capsid and the mechanism of action of lenacapavir. The narrative is compelling and well-supported by evidence, including structural studies, mutagenesis data, and clinical outcomes.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is high, with references to numerous published studies and clinical trials. The speaker acknowledges contributions from other labs and Gilead Sciences, providing a balanced view. The title accurately reflects the content, which focuses on the role of biochemistry in HIV treatment and prevention. The talk is well-structured and the claims are supported by data.

The title accurately reflects the content, focusing on the role of biochemistry in HIV treatment and prevention, with a strong emphasis on the speaker's contributions.

9/10

The speaker is a leading researcher in HIV capsid biology with three decades of experience. The talk presents peer-reviewed findings and clinical trial results, with a clear distinction between established facts and ongoing research. The content is highly reliable, though it reflects a personal perspective on the field's history.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 00:00Introduction and overview of the talk's structure.
• 01:00Presentation of clinical trial results showing lenacapavir's efficacy in preventing HIV infection.
• 05:00Explanation of the HIV capsid's structure and its role in the viral life cycle.
• 10:00Discussion of the fullerene cone model and the importance of pentameric defects.
• 15:00Description of the alanine scanning mutagenesis studies that identified the capsid as a drug target.
• 20:00Overview of the development of lenacapavir by Gilead Sciences, including medicinal chemistry efforts.
• 25:00Mechanism of action of lenacapavir, including its binding to the capsid and allosteric effects.
• 30:00Discussion of the global rollout of lenacapavir and future directions, including cell-free reconstitution.

• ASBMB Today article on Sundquist's work — Linked in the video description, provides additional information about Sundquist's research.
• ASBMB Annual Meeting proposals — Linked in the video description, related to the conference where the talk was given.

• Pornillos et al., Nature, 2011 — Structural studies of the HIV capsid hexamer and pentamer, supporting the fullerene cone model.
• Briggs et al., Structure, 2009 — Cryo-EM tomography of authentic HIV particles, confirming the capsid structure.

• Potential resistance to lenacapavir — While lenacapavir is highly effective, some studies have identified potential resistance mutations, though they often reduce viral fitness.